Great Novel Therapeutics Biotech & Medicals (ROCO:7427) Receivables Turnover : 0.03 (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Great Novel Therapeutics Biotech & Medicals Receivables Turnover?

The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Great Novel Therapeutics Biotech & Medicals's Revenue for the six months ended in Dec. 2023 was NT$0.09 Mil. Great Novel Therapeutics Biotech & Medicals's average Accounts Receivable for the six months ended in Dec. 2023 was NT$2.55 Mil. Hence, Great Novel Therapeutics Biotech & Medicals's Receivables Turnover for the six months ended in Dec. 2023 was 0.03.

Great Novel Therapeutics Biotech & Medicals Receivables Turnover Historical Data

The historical data trend for Great Novel Therapeutics Biotech & Medicals's Receivables Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Great Novel Therapeutics Biotech & Medicals Receivables Turnover Chart

Great Novel Therapeutics Biotech & Medicals Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Receivables Turnover

Get a 7-Day Free Trial

52.72

Great Novel Therapeutics Biotech & Medicals Semi-Annual Data
	Dec18	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Receivables Turnover	Get a 7-Day Free Trial					1.05	-	-	0.95	0.03

Competitive Comparison of Great Novel Therapeutics Biotech & Medicals's Receivables Turnover

For the Biotechnology subindustry, Great Novel Therapeutics Biotech & Medicals's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Great Novel Therapeutics Biotech & Medicals's Receivables Turnover Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Great Novel Therapeutics Biotech & Medicals's Receivables Turnover distribution charts can be found below:

* The bar in red indicates where Great Novel Therapeutics Biotech & Medicals's Receivables Turnover falls into.

Great Novel Therapeutics Biotech & Medicals Receivables Turnover Calculation

Receivables Turnover measures the number of times a company collects its average accounts receivable balance.

Great Novel Therapeutics Biotech & Medicals's Receivables Turnover for the fiscal year that ended in Dec. 2023 is calculated as

	Receivables Turnover (A: Dec. 2023 )
=	Revenue	/	Average Total Inventories
=	Revenue (A: Dec. 2023 )	/ (	(Accounts Receivable (A: Dec. 2022 )	+	Accounts Receivable (A: Dec. 2023 ))	/	count )
=	4.85	/ (	(0	+	0.092)	/	1 )
=	4.85	/	0.092
=	52.72

Great Novel Therapeutics Biotech & Medicals's Receivables Turnover for the quarter that ended in Dec. 2023 is calculated as

	Receivables Turnover (Q: Dec. 2023 )
=	Revenue	/	Average Total Inventories
=	Revenue (Q: Dec. 2023 )	/ (	(Accounts Receivable (Q: Jun. 2023 )	+	Accounts Receivable (Q: Dec. 2023 ))	/	count )
=	0.088	/ (	(5	+	0.092)	/	2 )
=	0.088	/	2.546
=	0.03

Great Novel Therapeutics Biotech & Medicals (ROCO:7427) Receivables Turnover Explanation

An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.

Great Novel Therapeutics Biotech & Medicals Receivables Turnover Related Terms

Thank you for viewing the detailed overview of Great Novel Therapeutics Biotech & Medicals's Receivables Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.

Great Novel Therapeutics Biotech & Medicals (ROCO:7427) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Great Novel Therapeutics Biotech & Medicals (ROCO:7427) » Definitions » Receivables Turnover

Comparable Companies

Traded in Other Exchanges

N/A

Address

No.3, Park Street, Room WR-06, 17th Floor, Nangang District, Taipei, TWN, 11503

Website

http://www.gntbm.com.tw

Great Novel Therapeutics Biotech & Medicals focuses on drug development to treat advanced cancer. The new drugs ranging from epigenetic modulators, a combination of tumor microenvironment-regulating agents, epigenetic immuno-modulators, to the protein degradation drugs targeting HDACs 1, 2, and 3, are in a developing pipeline. These drugs focus on the field of epigenetics, for the demand of clinical unmet needs in advanced and refractory cancers.

Great Novel Therapeutics Biotech & Medicals (ROCO:7427) Headlines

No Headlines